Capital Bluecross bioengineered skin coverage update | OpenPayer
RetiredCapital BluecrossPolicy MP 1.017
Bio-engineered Skin and Soft Tissue Substitutes
This policy describes medical necessity, investigational uses, product lists, and regulatory context for bioengineered skin and soft tissue substitutes used in wound care, burns, breast reconstruction, and specific dermatologic conditions for Capital Blue Cross programs.
Policy Summary
PayerCapital Bluecross
PolicyBio-engineered Skin and Soft Tissue Substitutes
Policy CodePolicy MP 1.017
Change TypeCriteria additions and revisions (material)
Effective Date4/1/2024
Next Review Date
Key ActionDocument required trial of conventional wound care and ABI ≥ 0.65 and confirm product will be used with conventional wound care when requesting authorization.
Title changed to match BCBSA (formerly Biologic and Burn Wound Dressings).
Added criteria for use of Alloderm for breast reconstruction.
For venous insufficiency ulcers treated with Apligraf, removed the ≥12-week ulcer duration requirement and changed conventional wound care trial from 8 weeks to 1 month; added requirement for standard therapeutic compression and an ABI ≥ 0.65 and use with conventional wound care.
For diabetic ulcers treated with Apligraf, changed conventional therapy trial from 4 weeks to 3 weeks; removed contraindication for heel wounds and removed requirement for absence of active Charcot's arthropathy; added requirement to use with conventional wound care and ABI ≥ 0.65.
Added requirement that the patient has adequate arterial blood supply documented by an Ankle-Brachial Index no less than 0.65 to support tissue growth.
Requirement that the patient has adequate arterial blood supply documented by an Ankle-Brachial Index (ABI) no less than 0.65.
Requirement that Apligraf be used in conjunction with conventional wound care regimens.
Added requirement that products (e.g., Dermagraft, Integra) must be used in conjunction with conventional wound care regimens.
Changed duration of conventional wound care therapy trial from 4 weeks to 3 weeks.
Oasis Wound Matrix now medically necessary for chronic, non-infected lower extremity ulcers with criteria including 1-month trial of conventional therapy and ABI >= 0.65.
Endoform Dermal Template changed from medically necessary to investigational for all indications.
Deleted contraindication for heel wounds.
Deleted requirement for absence of active Charcot's arthropathy.
Deleted general statements regarding documentation requirements and frequency of Apligraf and Dermagraft device application.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
manyproducts listed as investigational or not supported
dozensnamed bioengineered products cataloged
1 monthvenous ulcer trial before Apligraf
3 weeksdiabetic ulcer trial before Apligraf
ABI ≥ 0.65Ankle-Brachial Index threshold
≥30%Epicel® TBSA HDE threshold
Coverage Criteria and Indications
Medically necessary indications (selected, as listed)
Covered when ALL of the following condition-specific requirements are met for the listed products as described below:
Breast reconstruction using allogeneic acellular dermal matrix: When there is insufficient tissue expander or implant coverage by the pectoralis major muscle and additional coverage is required; or when there are viable but compromised or thin postmastectomy skin flaps at risk of dehiscence or necrosis; or when inframammary and lateral mammary folds have been undermined and reestablishment is needed.
Chronic noninfected full-thickness diabetic lower-extremity ulcers: Treatment using specified tissue-engineered skin substitutes (AlloPatch®, Apligraf®, Dermagraft®, Integra Omnigraft™, Integra Flowable Wound Matrix, Celera Dual Layer™, Signature APatch) when clinically appropriate per product labeling and policy mappings.
Products and Q-codes listed in policy (see chunks 1–2).
Chronic noninfected partial- or full-thickness lower-extremity ulcers due to venous insufficiency: Apligraf® is medically necessary for ulcers that have not adequately responded following a 1-month period of conventional ulcer therapy.1 month trial of conventional therapy
Specific to Apligraf® (Q4101).
Dystrophic epidermolysis bullosa: Use of OrCel™ for mitten-hand deformity when standard wound therapy has failed and when provided in accordance with the FDA HDE specifications.HDE compliance
OrCel™ mapped to Q4100.
Second- and third-degree burns: Epicel® is medically necessary for deep dermal or full-thickness burns comprising total body surface area ≥30% when provided in accordance with FDA HDE specifications; Integra Dermal Regeneration Template is medically necessary for selected burns per product labeling and evidence.TBSA >= 30% for Epicel®
Epicel® HDE; Integra supported by comparative studies.
Investigational / Not covered uses
All other uses of the listed substitutes, and listed products not otherwise specified as medically necessary, are considered investigational.
Investigational products: All other skin and soft tissue substitutes not listed as medically necessary in this policy are considered investigational, including the extensive enumerated product list in the policy (see chunks 3–7).
Numerous products explicitly listed as investigational in the document.
Breast reconstruction — covered with evidence-based considerations
Breast reconstruction
Breast reconstruction with allogeneic ADM: Evidence includes randomized controlled trials and systematic reviews. While overall complication rates may be similar to standard procedures, ADM reconstruction has higher rates of seroma, infection, and necrosis but may reduce capsular contracture and implant malposition; evidence is sufficient to determine a meaningful improvement in net health outcome for selected reconstruction scenarios with limited tissue coverage.
Use case-specific benefits and risks should inform shared decision-making.
Tendon repair — insufficient evidence
Tendon repair
Rotator cuff repair with Graftjacket: One randomized controlled trial found improved outcomes with Graftjacket ADM for rotator cuff repair; however, additional larger studies are needed and current evidence is insufficient to determine effects on health outcomes.
Insufficient evidence; not established as broadly effective.
Hernia/parastomal reinforcement — not supported/unlikely to improve net health outcome
Hernia or parastomal reinforcement
Use of acellular collagen-based scaffolds for hernia/parastomal reinforcement: Several comparative studies, including randomized trials, have shown no difference in outcomes compared with synthetic mesh or no reinforcement; the technology is unlikely to improve net health outcome.
Not supported for hernia/parastomal reinforcement based on available evidence.
Products with RCT-demonstrated efficacy: AlloPatch, Apligraf, Dermagraft, and Integra have randomized controlled trial evidence demonstrating efficacy over standard care for chronic, noninfected diabetic lower-extremity ulcers.
These products are considered medically necessary for appropriate diabetic ulcer indications per policy mappings.
Other ADM products for diabetic ulcers: For ADM products other than those listed (e.g., DermACELL, Graftjacket, TheraSkin, Cytal, PriMatrix, Oasis), evidence is limited or insufficient; some subgroup benefit noted (e.g., DermACELL single-application subgroup), but overall insufficient to determine effect on health outcomes.
Additional studies needed to define beneficiary populations.
Venous ulcers — product-specific coverage (examples and criteria)
Venous insufficiency lower-extremity ulcers
Apligraf and Oasis: Randomized controlled trials have demonstrated efficacy of Apligraf and Oasis Wound Matrix over standard of care for venous ulcers; coverage is supported when consistent with trial-based indications and policy requirements.
Apligraf coverage requires prior conventional therapy trial of 1 month per policy.
Other substitutes for venous ulcers: Dermagraft was not shown to be more effective than controls in a large RCT for the overall population and showed limited subgroup benefits; evidence is insufficient for many other products for venous ulcers.
Insufficient evidence for broad coverage of other products.
Dystrophic epidermolysis bullosa — limited/HDE use (OrCel example)
Dystrophic epidermolysis bullosa
OrCel for dystrophic epidermolysis bullosa undergoing hand reconstruction: OrCel received approval under an FDA humanitarian device exemption for use in patients with dystrophic epidermolysis bullosa undergoing hand reconstruction (to close and heal surgical wounds including donor sites); evidence consists mainly of small case series and is limited to HDE-specified use.HDE compliance
OrCel mapped to Q4100; use limited to HDE indication.
Coverage by indication — Coverage conclusions vary by indication and product
Coverage conclusions vary by indication and product:
Dystrophic Epidermolysis Bullosa (OrCel): OrCel is FDA-approved under an HDE for hand reconstruction in dystrophic epidermolysis bullosa; evidence is limited (small series) and use is restricted to the HDE specifications.
HDE-specific use only.
Deep dermal/full-thickness burns (Epicel, Integra): Epicel is FDA-approved under an HDE for deep dermal or full-thickness burns involving ≥30% TBSA; Integra has comparative studies showing improved outcomes for burns—coverage varies by product-specific evidence and labeling.Epicel: >=30% TBSA
Product-specific approvals and evidence vary.
Chronic neuropathic diabetic lower-extremity ulcers: Certain products (mapped to Q4260 and other listed Q-codes) are covered when medically necessary for chronic, non-infected, full-thickness neuropathic diabetic lower-extremity ulcers per listed ICD-10 codes.
Covered Indications
Covered when medically necessary for the following indications
Covered indications (summary): Use of bio-engineered skin and soft tissue substitutes identified by specific HCPCS Q-codes is covered when medically necessary for: venous insufficiency ulcers; dystrophic epidermolysis bullosa (per HDE); second- and third-degree burns (with coverage for burns >30% TBSA specified); and other chronic non-pressure lower-extremity ulcers mapped to listed ICD-10 codes.
See coding and product sections for exact Q-code and ICD-10 mappings.
Modified coverage prerequisites (history)
Policy modifications and coverage prerequisites referenced in history
Venous insufficiency ulcers treated with Apligraf: Must meet all: (1) completed conventional wound care trial of 1 month; (2) used with standard therapeutic compression; (3) patient has adequate arterial blood supply documented by an Ankle-Brachial Index no less than 0.65; (4) used in conjunction with conventional wound care regimens.ABI >= 0.65; 1 month trial
Previous criterion requiring ulcer duration ≥12 weeks was deleted; changes effective per policy history.
Diabetic foot ulcers treated with Apligraf: Must meet all: (1) completed conventional wound care trial of 3 weeks; (2) used in conjunction with conventional wound care regimens; (3) patient has adequate arterial blood supply documented by ABI ≥ 0.65; (4) prior contraindication for heel wounds and requirement for absence of active Charcot's arthropathy were removed.ABI >= 0.65; 3 week trial
Duration of prior conservative therapy shortened from 4 weeks to 3 weeks.
Eligibility (modified)
Covered when ALL of the following are met
Eligibility prerequisites: 1) Apligraf (or other specified product where required) is used in conjunction with conventional wound care regimens; 2) The patient has adequate arterial blood supply documented by an Ankle-Brachial Index no less than 0.65.ABI >= 0.65
Prior exclusions for heel wounds and for active Charcot's arthropathy were removed in the update; documentation of concomitant conventional care is required.
Examples of product-specific coverage statements captured in this section:
Oasis Wound Matrix - venous insufficiency ulcers: Chronic, non-infected, partial- or full-thickness lower-extremity skin ulcers due to venous insufficiency are medically necessary when all conditions are met: inadequate response following a 1-month period of conventional ulcer therapy; patient has adequate arterial blood supply documented by ABI ≥ 0.65; product is used in conjunction with conventional wound care regimens.ABI >= 0.65; 1 month trial
Use for other wounds not meeting these criteria is investigational.
Dermagraft and similar living-cell products: Must be used in conjunction with conventional wound care regimens; additional product-specific criteria and prior conservative therapy durations apply as noted in policy history.Concomitant conventional care documented
Duration of prior conservative therapy revised in policy history (e.g., 3 weeks for diabetic ulcers).
All other uses of the bioengineered skin and soft tissue substitutes listed in this policy that are not specifically identified as medically necessary are considered investigational. The policy states there is insufficient evidence to conclude these other uses improve health outcomes, and products not listed as medically necessary are treated as investigational (see the policy's extensive investigational product list).
Requests for investigational uses may be denied and should include documentation demonstrating the indication matches a listed medically necessary condition when applicable.
Use of acellular collagen-based scaffolds or tissue-engineered skin substitutes for hernia repair or parastomal reinforcement is not supported by the evidence. Several comparative studies, including randomized controlled trials, have shown no difference in clinical outcomes versus synthetic mesh or no reinforcement; therefore these applications are unlikely to improve net health outcome.
The policy lists numerous skin substitute products that are considered investigational when used outside the medically necessary indications described in this document. Examples are provided in the investigational product list and include many named products throughout the policy; see the investigational section for the full enumerated list.
Administrative language that previously set out general documentation requirements and explicit frequency guidance for application of Apligraf® and Dermagraft® was deleted from the policy. Remaining requirements continue to emphasize that use must be supported by indication-specific documentation and that products are used in conjunction with conventional wound care when specified.
The prior explicit contraindication excluding treatment of heel wounds was removed from the policy. Heel wounds are no longer listed as a contraindication for the referenced products in the updated criteria.
Use of Oasis® Wound Matrix (Q4102) is considered investigational for wounds that do not meet the policy-specified criteria. Oasis is now medically necessary for chronic, noninfected, partial- or full-thickness lower-extremity ulcers due to venous insufficiency only when all criteria (including a 1-month trial of conventional therapy and adequate arterial perfusion) are met; other indications remain investigational.
Endoform Dermal Template is designated investigational for all indications in this policy and therefore is not covered for any use.
Throughout the policy, a set of products and uses are explicitly designated investigational — i.e., not medically necessary — unless specifically listed as medically necessary. The investigational list is extensive and names many devices and biologic substitutes; identified investigational items should be treated as noncovered unless and until criteria designate them medically necessary.
The policy specifically notes that tissue-engineered skin substitutes used for hernia or parastomal reinforcement are not expected to improve outcomes compared with standard synthetic mesh or no reinforcement based on available RCTs and comparative studies; therefore these applications are not supported by the evidence.
Coding and Diagnosis Codes
Named product HCPCS/Q-codesHCPCS | mixed
Q4116
AlloDerm®
Q4100
AlloMend® / Cortiva® / DermaMatrix ™ / OrCel™ / Epicel® (entries referenced with Q4100/HDE as applicable)
ICD-10 diagnosis codes for chronic non-pressure ulcersICD-10
L97.822
Non-pressure chronic ulcer of other part of left lower leg with fat layer exposed
L97.825
Non-pressure chronic ulcer of other part of left lower leg with muscle involvement without evidence of necrosis
L97.826
Non-pressure chronic ulcer of other part of left lower leg with bone involvement without evidence of necrosis
L97.828
Non-pressure chronic ulcer of other part of left lower leg with other specified severity
L97.915
Non-pressure chronic ulcer of unspecified part of right lower leg with muscle involvement without evidence of necrosis
L97.916
Non-pressure chronic ulcer of unspecified part of right lower leg with bone involvement without evidence of necrosis
L97.918
Non-pressure chronic ulcer of unspecified part of right lower leg with other specified severity
L97.925
Non-pressure chronic ulcer of unspecified part of left lower leg with muscle involvement without evidence of necrosis
L97.926
Non-pressure chronic ulcer of unspecified part of left lower leg with bone involvement without evidence of necrosis
L97.928
Non-pressure chronic ulcer of unspecified part of left lower leg with other specified severity
1–10 of 16
1/2
ICD-10 diagnosis codes for venous insufficiency/chronic venous hypertension and dystrophic epidermolysis bullosaICD-10
I87.2
Venous insufficiency (chronic) (peripheral)
I87.311
Chronic venous hypertension (idiopathic) with ulcer of right lower extremity
I87.312
Chronic venous hypertension (idiopathic) with ulcer of left lower extremity
I87.313
Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity
I87.331
Chronic venous hypertension (idiopathic) with ulcer and inflammation of right lower extremity
I87.332
Chronic venous hypertension (idiopathic) with ulcer and inflammation of left lower extremity
I87.333
Chronic venous hypertension (idiopathic) with ulcer and inflammation of bilateral lower extremity
Q81.2
Epidermolysis bullosa dystrophica
Policy-related HCPCS/Q/A codes (selected history entries)HCPCS
Q4122
Updated description (refer to policy history)
Q4165
Updated description (refer to policy history)
Q4179
HCPCS code added 1/1/18
Q4182
HCPCS code added 1/1/18
Q4193
Added effective 1/1/19
Q4195
Added effective 1/1/19
Q4196
Added effective 1/1/19
Q4197
Added effective 1/1/19
Q4200
Added effective 1/1/19
Q4202
Added effective 1/1/19
1–10 of 72
1/8
Total body surface area (TBSA) — Epicel® HDE indication threshold
Epicel® HDE TBSA threshold>= 30% total body surface area (TBSA) for deep dermal or full-thickness burns (per FDA HDE)
Product mapping / codeEpicel® referenced with Q4100 in policy text
Use contextMay be used in conjunction with split-thickness autografts or alone when autograft not an option due to severity/extent
Conventional ulcer therapy trial — venous insufficiency prior to Apligraf
Prior Authorization, Documentation, and Denial Risk
Prior Authorization
Prior Authorization Required
Prior authorization may be required for use of certain bioengineered skin, soft tissue, and ADM products and for specific HCPCS Q‑codes. Verify member benefits and any program‑specific prior authorization requirements before scheduling or performing services.
Prior authorization may be required for HCPCS Q‑codes referenced in this policy (examples include Q4100, Q4101, Q4102, Q4105, Q4122, Q4128, Q4260, Q4259).
Coverage for a given code is determined by the member's health benefit plan; identification of a code here does not guarantee coverage.
Prior authorization rules vary by product/program (e.g., FEP PPO) — check plan-specific prior authorization processes and forms.
Prior Authorization
Prior Authorization: Conservative Therapy Trials and Adjunctive Use
Document that appropriate conservative/wound care trials were completed prior to advanced product use, and that vascular status and adjunctive use requirements are met where specified.
Venous insufficiency lower‑extremity ulcers: document failure to adequately respond after a 1‑month trial of conventional ulcer therapy (including compression).
Definitions and Product Types
Acellular dermal matrix (ADM) — definition and properties
DefinitionAcellular dermal matrix (ADM): allograft derived from donated human skin with cellular components removed, leaving a matrix/scaffold composed of collagen and other extracellular matrix components
PropertiesProcessing removes viable cells to reduce rejection/infection; preserved dermal structure used as scaffold for tissue repair
Regulatory contextHuman-derived ADM often classified as banked human tissue and may not require FDA premarket approval for homologous use when minimally manipulated
DefinitionCellular products: skin substitutes that contain living cells such as fibroblasts and keratinocytes within a matrix
Cell sources
Background and Scope
Bioengineered skin substitutes encompass both acellular dermal matrices (ADMs) and cellular living‑cell products. ADMs are human- or animal-derived dermal tissue processed to remove cells and preserve the extracellular matrix scaffold; cellular products contain viable cells (for example, fibroblasts and keratinocytes) within a matrix. These products are used as temporary or permanent wound coverings across indications including chronic nonhealing ulcers, burns, breast reconstruction when tissue coverage is inadequate, and select dermatologic conditions; however, coverage and medical necessity vary by product and indication as described in this policy.
Policy Revision History and Changes
material_changesLatest
Added criteria for use of AlloDerm for breast reconstruction; shortened conservative therapy trials for venous and diabetic ulcers (venous: trial of conventional wound care changed from 8 weeks to 1 month; diabetic: from 4 weeks to 3 weeks); added requirement for therapeutic compression for Apligraf use in venous ulcers; added requirement that products be used in conjunction with conventional wound care regimens; added requirement for adequate arterial blood supply documented by Ankle-Brachial Index >= 0.65; deleted contraindication for heel wounds and requirement for absence of active Charcot's arthropathy; deleted general statements regarding documentation requirements and device application frequency.
2018-01-01coding_update
Multiple HCPCS codes (e.g., Q4179, Q4182) were added in prior years (listed in policy history entries).
Policy Summary
PayerCapital Bluecross
PolicyBio-engineered Skin and Soft Tissue Substitutes
Policy CodePolicy MP 1.017
Change TypeCriteria additions and revisions (material)
Effective Date4/1/2024
Next Review Date
Key ActionDocument required trial of conventional wound care and ABI ≥ 0.65 and confirm product will be used with conventional wound care when requesting authorization.
Venous insufficiency ulcers: Products mapped to Q4101, Q4102, Q4260 and related codes are covered when medically necessary for venous insufficiency ulcers, subject to policy criteria (e.g., prior conservative therapy trial).
Coverage contingent on medical necessity and benefit plan.
AlloDerm for breast reconstruction:
Criteria for use of AlloDerm in breast reconstruction were added to align with BCBSA-adopted changes (see policy history); refer to product-specific section for details.
Operational change noted in history; see full policy for exact criteria.
Integra is medically necessary for diabetic foot ulcers per policy mapping; requires use with conventional wound care regimens and ABI documentation where specified.
Per product rules; ABI documentation when required
Integra Omnigraft moved to medically necessary for specified indications.
Required conservative therapy duration (venous ulcers) before Apligraf1 month of conventional ulcer therapy (must have not adequately responded)
Product specificApligraf® (Q4101) — indication for venous insufficiency lower-extremity ulcers
ContextConventional therapy includes compression when appropriate per standard wound care definition
Ankle-Brachial Index — documented requirement no less than 0.65
ABI documentation requirementAnkle-Brachial Index documented as no less than 0.65 to support tissue growth
PurposeDemonstrate adequate arterial blood supply to attempt healing and support tissue growth
Diabetic ulcer conservative therapy duration3 weeks (duration of conventional wound care trial revised from 4 weeks to 3 weeks)
Venous ulcer conservative therapy duration1 month required for venous insufficiency ulcers prior to Apligraf or Oasis Wound Matrix
Concurrent care requirementProducts must be used in conjunction with conventional wound care regimens (added requirement)
Diabetic lower‑extremity ulcers: document a trial of conventional wound care for at least 3 weeks prior to use of certain products (e.g., Apligraf, Dermagraft, Integra).
Apligraf and similar products must be used as an adjunct to conventional wound care regimens (compression/off‑loading, debridement, infection control, nutrition optimization, dressings).
Document that vascular sufficiency has been assessed and corrected when possible (see ABI requirement).
Denial Risk
Vascular Status (ABI) and Denial Risk
Demonstrate adequate arterial blood supply when required; lack of documentation may result in denial.
When specified in criteria (for example Apligraf, Oasis, Integra uses), document an Ankle‑Brachial Index (ABI) ≥ 0.65 consistent with policy requirements.
If ABI < 0.65, or ABI not documented, the request may be denied for insufficient vascular supply to support tissue growth.
Document any vascular interventions or optimization performed prior to advanced product use.
Billing Rule
Coding and Coverage Determination
Coding listed in this policy is a guide; coverage and billing determination depend on the member's benefit plan and prior authorization. Use the policy coding list and confirm applicability of newly effective codes.
Follow the policy's coding list when submitting claims; new codes effective 1/1/2024 were added — verify which codes are considered medically necessary vs investigational for the member.
Identification of a code in the coding section does not guarantee coverage — benefits are plan‑dependent.
Some HCPCS Q‑codes in this policy are explicitly listed as investigational for certain uses; prior authorization may still be required but coverage may be denied.
Denial Risk
Investigational Uses — Denial Risk
Use of products outside the medically necessary indications listed in this policy is considered investigational and may be denied.
Requests for indications not listed as medically necessary (including many repair, reinforcement, or cosmetic uses) will be reviewed and may be denied as investigational.
Hernia/parastomal reinforcement and other unsupported indications frequently lack sufficient evidence — expect potential denial for such uses.
Prior Authorization
Benefit Verification Required
Verify that the requested service is a covered benefit under the member's specific health benefit plan prior to authorization or provision of service.
Medical policy guidance does not replace the member's benefit plan; benefit limits, exclusions, and prior authorization requirements are defined by the plan.
Contact Capital BlueCross or use the member's benefit portal to confirm coverage, prior authorization requirements, and any plan‑level limits before proceeding.
Documentation Required
Indication‑ and Product‑Specific Documentation
Provide indication‑specific and product‑specific documentation that maps the diagnosis and wound characteristics to policy criteria.
Document the specific product used (brand, formulation, HCPCS code) and the exact wound characteristics (location, size, depth, duration, presence/absence of infection, tunneling).
Map the diagnosis to appropriate ICD‑10 codes listed in the policy (e.g., L97.x codes for chronic lower‑extremity ulcers, I87.x for venous insufficiency, Q81.2 for dystrophic epidermolysis bullosa).
Document that standard/wound care measures were attempted prior to advanced product use (compression, off‑loading, debridement, infection control, nutrition).
Denial Risk
Documentation‑Linked Denials and Denial Triggers
Missing or incomplete documentation of required trials, ABI, adjunctive use, or diagnosis-to-code mapping is a common reason for denial; ensure records explicitly show criteria were met.
Include progress notes, wound measurements (with dates), photos if available, ABI results, debridement records, and documentation of compression/off‑loading or other standard therapies.
If prior authorization is requested, attach the documentation showing the conservative therapy trial length and outcomes.
Requests lacking documentation that the product was used with conventional wound care regimens, or lacking ABI documentation when required, may be denied.
Cells may be autologous, allogeneic, or xenogeneic (derived from other species)
FunctionProvide viable cells and extracellular matrix and may deliver growth factors to stimulate wound healing
Acellular dermal matrix (ADM) — alternate definition and context for use
Alternate ADM descriptionHuman or animal-derived dermal tissue processed to remove cells while preserving dermal structure, used as a scaffold for tissue repair
ExamplesExamples include AlloDerm®, Graftjacket®, DermACELL™
Processing noteProducts differ by species source, processing, additives, hydration, and preparation requirements
Living cell therapy — products containing living human cells
Living cell therapy definitionProducts containing living human cells (e.g., Apligraf®, Dermagraft®, TheraSkin®) intended to promote wound healing by providing viable cells and extracellular matrix
ExamplesApligraf® (bilayered with keratinocytes and fibroblasts), Dermagraft® (cryopreserved fibroblasts on scaffold), TheraSkin® (cryopreserved split-thickness allograft with living cells)
Regulatory statusSome cellular products have FDA premarket approval for specific ulcer indications
Ankle-Brachial Index (ABI) — definition and clinical interpretation
DefinitionAnkle-Brachial Index (ABI): noninvasive test dividing ankle systolic pressure by brachial systolic pressure to assess arterial insufficiency
Interpretation rangesABI >1.3 calcified; ABI >=0.9–1.3 normal; ABI >=0.4–0.9 arterial obstruction; ABI <0.4 multilevel disease
Clinical useDetermines adequacy of arterial blood supply to attempt wound healing; informs interventions if inadequate
Conventional wound therapy definitionConventional wound therapy includes vascular assessment/correction, nutrition optimization, debridement, maintenance of a clean moist bed, off-loading, and treatment of infection
Role prior to advanced therapyExpected and must be documented prior to or concurrent with advanced skin substitute use; serves as the comparator in trials
Trial durationsPolicy specifies trial durations prior to some advanced products (e.g., 3 weeks for diabetic ulcers; 1 month for venous ulcers)
Diabetic Neuropathic Ulcers — definition and common features
DefinitionDiabetic neuropathic ulcers: ulcers due to loss of protective sensation and foot deformities in diabetic patients; typically painless and located at areas of repeated trauma
Common featuresMay show hyperkeratotic tissue, undermined borders, lack of sensation, and signs of neuropathy on exam
Clinical relevanceDistinguishes neuropathic from ischemic ulcers and guides need for vascular assessment (ABI)
Q4100 — code mapping for OrCel™ referenced in policy
Q4100 mappingQ4100 identified as the HCPCS code to use for OrCel™ (policy explicitly: 'Use Q4100 for OrCel™')
Associated indicationOrCel™ used for dystrophic epidermolysis bullosa (HDE) mitten-hand deformity per policy
Coding noteQ4100 is also referenced for some HDE products such as Epicel® in policy text
HCPCS Q-codes referencedCovered HCPCS Q-codes referenced include Q4101, Q4102, Q4105, Q4260 among others
Use mappingThese Q-codes are mapped to specific products and indications in the policy (e.g., Q4101 = Apligraf®, Q4102 = Oasis™ Wound Matrix)
Prior authorization notePrior authorization may be required per member benefit plan for medically necessary use of listed Q-codes
Ankle-Brachial Index (ABI) — reiteration of ABI requirement (>= 0.65) to support tissue growth when using certain biologic products
ABI policy requirementPolicy requires ABI no less than 0.65 to support tissue growth when using certain bioengineered products
Eligibility impactABI requirement operationalized as part of eligibility criteria for products such as Apligraf and Oasis
DocumentationABI must be documented in the medical record to demonstrate adequate arterial blood supply
Ankle-Brachial Index (ABI) — restated definition and numeric threshold callout (>= 0.65)
ABI restatedAnkle-Brachial Index (ABI) — a noninvasive vascular test; policy requires ABI no less than 0.65 to demonstrate adequate arterial blood supply
Clinical interpretationProvides thresholds for arterial sufficiency relevant to wound healing decisions
2019-01-01coding_update
Additional HCPCS/Q-codes were added effective 1/1/2019 (examples include Q4193, Q4195–Q4197, Q4200, Q4202, Q4203).
2020-07-01coding_update
A series of HCPCS Q-codes were added 7/1/20 (Q4231–Q4239, Q4240–Q4242, Q4244–Q4248) and others added 10/1/20 (e.g., Q4249, Q4254) as reflected in policy history.
2021-09-22coding_update
Codes added earlier (amniotic-related Q4228, Q4236 and others) were later deleted or reclassified per cross-reference and history entries on/around 9/22/2021.
2022-06-13coding_update
New codes Q4259 and Q4260 were added as medically necessary and Q4261 added as investigational; effective 7/1/2022 as noted in the policy history.
2023-09-07coding_update
Administrative update added A2022–A2025 and Q4285 effective 10/2023 as recorded in the policy history.
2023-12-13coding_updateLatest
Administrative update added a large set of HCPCS Q-codes (Q4279, Q4288–Q4304) with an effective date of 1/1/2024 for policy coding lists and coverage determination.
The change log documents deletions of general administrative statements and product-application frequency language (for example, references to Apligraf® and Dermagraft® application frequency) that were removed as non-material edits. These deletions do not alter the core clinical eligibility requirements added or retained elsewhere in the policy (such as ABI thresholds and specified conventional therapy trial durations).